What you are comparing
An FDA-approved hormone went through a new-drug or generic pathway. Identity, strength, quality, labeled indications, and post-marketing rules attach to that product. Examples include estradiol patches and gels, some oral estradiols, oral micronized progesterone, vaginal estrogen for genitourinary symptoms, and several testosterone gels or injections for indicated male hypogonadism. You get a package insert, a recall system, and a milligram that is supposed to match the label.
A compounded hormone is prepared for an individual by a 503A pharmacy or, less often, a 503B outsourcing facility. Compounding is legal and sometimes necessary. It is not a substitute for a clinical trial. Mixes may include Bi-Est, Tri-Est, custom testosterone or DHEA creams, troches, and many pellet programs. FDA compounding pages exist because quality can vary and because compounding is meant for needs that approved products do not meet.
Marketing often collapses this into “natural BHRT versus synthetic HRT.” That is the wrong split. ACOG notes that “bioidentical” is used to imply safer and more effective care without evidence. NAMS 2022 says government-approved bioidentical estradiol and micronized progesterone already exist. A compounded cream can be chemically similar and less regulated. Approval and compounding are manufacturing paths, not virtue scores.
This comparison is for people considering menopause hormone therapy or testosterone who are being steered to a custom mix or pellet as the default. It is not a license to refuse all hormone therapy because a compounder disappointed you. Endocrine Society menopause guidance still treats indicated, individualized hormone therapy as medical care with risks and benefits.
How they differ
Evidence and labeling differ first. Approved products carry trial-based inserts and boxed warnings where FDA requires them. Compounded products usually do not. NAMS lists overdosing, underdosing, impurities, sterility gaps, and missing risk labels as compounding concerns. Outcome trials attach to specific products and routes. They do not automatically transfer to a logbook recipe.
Dose certainty differs next. A patch is designed to deliver a labeled estradiol range. A cream jar can vary by pharmacy, skin absorption, and how much you apply. Endometrial protection is a clinical yes-or-no if you have a uterus and take systemic estrogen. Do not assume a compounded progesterone cream equals labeled oral micronized progesterone. Bleeding still needs a protocol.
Access and cost differ. Generics of approved estradiol and progesterone are often covered. Membership compounding programs commonly bill cash monthly. Pellets add insertion fees and are hard to reverse if levels run high. Insurance coverage is not a safety certificate, but cash-only custom care can hide the absence of a labeled alternative.
- Approved: labeled dose, insert, manufacturing standards, easier coverage.
- Compounded: individual recipe, fewer trials, quality depends on the pharmacy.
- Neither path: “natural” as a synonym for no monitoring or no thrombosis risk.
Who each option is for
Start with an approved product when it matches the indication: vasomotor symptoms, genitourinary syndrome, or confirmed hypogonadism after appropriate labs. Endocrine Society and NAMS frame menopause therapy as a shared decision about symptoms, age, timing, and contraindications such as unexplained bleeding, hormone-sensitive cancer history, or prior venous thromboembolism—not as a spa optimization.
Compounding may fit a documented excipient allergy, an unavailable strength, or a route you cannot use in a labeled form after a real trial. It may also appear in some testosterone situations for women where no FDA-approved female product exists; that is still an off-label, monitored decision—not a pellet mill. Ask why the labeled male-dose gel, adjusted carefully, or another approved option failed.
Custom mixes are a poor default if the clinic’s only offering is saliva-titrated Bi-Est and a pellet on visit one. NAMS finds saliva-guided dosing unreliable. People with a uterus who need systemic estrogen need a progestogen plan with endometrial logic. People who want fertility preserved should not start testosterone protocols that suppress spermatogenesis without counseling.
Neither option is first-line for unexplained postmenopausal bleeding, a new breast mass, or acute chest pain and leg swelling. Those need evaluation. Hormone shopping is not an ER substitute.
Risks of choosing the wrong one
Choosing compounded care because it is marketed as more natural can mean under-protected endometrium, uneven dosing, or a sterile-product gap. ACOG advises counseling that approved therapies are recommended over routine compounded BHRT. Preference is allowed; skipping that counseling is not good care.
Refusing all approved estradiol because a friend had a compounded brand story can leave severe vasomotor symptoms, sleep loss, and bone risk unaddressed. WHI-era oral conjugated estrogen plus medroxyprogesterone is not every modern product. Route and timing matter. The wrong lesson from one trial is to treat every estrogen as identical—or as automatically toxic.
Pellets you cannot stop quickly raise a practical harm: erythrocytosis, mood change, or bleeding that lasts until the implant fades. Saliva-only titration can chase noise and escalate stacks of DHEA, testosterone, and estriol without an indication. Missing mammography or a bleeding protocol is a clinic-process failure, not a molecule failure.
Quality failures are uncommon in good pharmacies and still more likely when nobody can name the compounder. FDA compounding oversight exists because past contamination events were real. Ask for the pharmacy and the reason approved products were inadequate.
How to decide
Write the indication in one line. If an approved estradiol patch or vaginal product and, when needed, oral micronized progesterone can treat it, start there. Ask what would make the clinician switch to compounding. If the answer is “our protocol” or “your saliva is off,” get another opinion.
If compounding is proposed, get the pharmacy name, sterile versus nonsterile process, 503A or 503B status, and a monitoring plan that includes bleeding, blood pressure, and, for testosterone, hematocrit. NAMS and ACOG both want that conversation documented. Prefer the smallest custom change that solves the actual gap.
Price the year, including insertions, extra labs, and memberships. A labeled generic can be less expensive than a boutique cream with the same estradiol molecule. Cost is not evidence, but opacity often tracks a business model.
Keep screening and contraindications. Breast-cancer history, prior VTE, unexplained bleeding, and pregnancy plans change the pathway more than a brand name. Use licensed clinicians who will prescribe an approved product if you refuse compounding. That willingness is a useful quality signal.
Frequently Asked Questions
References
ACOG Clinical Consensus: Compounded Bioidentical Menopausal Hormone Therapy
https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapyNAMS: 2022 Hormone Therapy Position Statement
https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdfFDA: Human Drug Compounding
https://www.fda.gov/drugs/human-drug-compoundingEndocrine Society: Treatment of Symptoms of the Menopause Clinical Practice Guideline
https://www.endocrine.org/clinical-practice-guidelines/treatment-of-symptoms-of-the-menopause
Your Privacy Choices